[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20050226940A1 - Antitumour compositions containing taxane derivatives - Google Patents

Antitumour compositions containing taxane derivatives Download PDF

Info

Publication number
US20050226940A1
US20050226940A1 US11/149,178 US14917805A US2005226940A1 US 20050226940 A1 US20050226940 A1 US 20050226940A1 US 14917805 A US14917805 A US 14917805A US 2005226940 A1 US2005226940 A1 US 2005226940A1
Authority
US
United States
Prior art keywords
topoisomerase inhibitor
taxane
taxotere
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/149,178
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9435406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050226940(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to US11/149,178 priority Critical patent/US20050226940A1/en
Publication of US20050226940A1 publication Critical patent/US20050226940A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)

Definitions

  • the present invention relates to combinations of taxol, Taxotere and their analogues and substances which are therapeutically useful in the treatment of neoplastic diseases.
  • Taxol, Taxotere and their analogues which possess noteworthy antitumour and antileukaemic properties, are especially useful in the treatment of cancers of the ovary, breast or lung.
  • the doses used are between 1 and 10 mg/kg administered intraperitoneally or between 1 and 3 mg/kg administered intravenously.
  • taxol, Taxotere and their analogues may be considerably improved when they are administered in combination with at least one substance which is therapeutically useful in anticancer treatments and has a mechanism identical to or different from this of taxane derivatives.
  • alkylating agents such as cyclophosphamide; isosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine, antimetabolites such as pyrimidine analogues, for instance 5-fluorouracil and cytarabine or its analogues such as 2-fluorodeoxycytidine, or folic acid analogues such as methotrexate, idatrexate or trimetrexate, spindle poisons including vinca alkaloids such as vinblastine or vincristine or their synthetic analogues such as navelbine, or estramustine or taxoids, epidophylloptoxins such as etoposide or teniposide, antibiotics such as daunorubicine, doxorubicin, bleomycin or mitomycin, enzymes such as L
  • the activity of the products depends on the doses used, it is possible to use higher doses and to increase the activity while decreasing the toxicity phenomena or delaying their onset by combining growth factors of the haematopoietic type such as G-CSF or GM-CSF or certain interleukins with taxol, Taxotere, their analogues or their combinations with other therapeutically active substances.
  • growth factors of the haematopoietic type such as G-CSF or GM-CSF or certain interleukins with taxol, Taxotere, their analogues or their combinations with other therapeutically active substances.
  • the combinations or associations according to the invention enable the phenomenaa of pleiotropic resistance or “multi-drug resistance” to be avoided to delayed.
  • the invention relates to combinations of taxol, Taxotere and their analogues with vinca alkaloids, cyclophosphamide, 5-fluorouracil, doxorubicin, cisplatin and etoposide.
  • the efficacy of a combination according to the invention may also be characterized by adding the actions of each constituent.
  • a combination manifests therapeutic synergy if it is therapeutically superior to one or other of the constituents used at its optimum dose (T. H. CORBETT et al., Cancer Treatment Reports, 66, 1187 (1982))
  • a product is considered to be active if log 10 cells killed is greater than or equal to 0.7.
  • a product is considered to be very active if log 10 cells killed is greater than 2.8.
  • the combination, used at its own maximum tolerated dose, in which each of the constituents will be present at a dose generally not exceeding its maximum tolerated dose, will manifest therapeutic synergy when the log 10 cells killed is greater than the value of the log 10 cells killed of the best constituent when it is administered alone.
  • mice The animals subjected to the experiment, generally mice, are subcutaneously grafted bilaterally with 30 to 60 mg of a tumour fragment on day 0.
  • the animals bearing tumours are mixed before being subjected to the various treatments and controls.
  • tumours are allowed to develop to the desired size, animals having insufficiently developed tumours being eliminated.
  • the selected animals are distributed at random to undergo the treatments and controls.
  • Animals not bearing tumours may also be subjected to the same treatments as the tumour-bearing animals in order to be able to dissociate the toxic effect from the specific effect on the tumour.
  • Chemotherapy generally begins from 3 to 22 days after grafting, depending on the type of tumour, and the animals are observed every day.
  • the different animal groups are weighed 3 or 4 times a week until the maximum weight loss is attained, and the groups are then weighed at least once a week until the end of the trial.
  • tumours are measured 2 or 3 times a week until the tumour reaches approximately 2 g, or until the animal dies if this occurs before the tumour reaches 2 g.
  • the animals are autopsied when sacrificed.
  • the antitumour activity is determined in accordance with the different parameters recorded.
  • the animals are grafted with a particular number of cells, and the antitumour activity is determined by the increase in the survival time of the treated mice relative to the controls.
  • the product is considered to be active if the increase in survival time is greater than 27%, and is considered to be very active if it is greater than 75% in the case of P388 leukaemia.
  • Taxotere and various chemotherapeutic agents, such as cyclophosphamide (alkylating agent), 5-fluorouracil (antimetabolite), etoposide (semisynthetic podophyllotoxin agent) and vincristine (vinca alkaloid), the combinations being used at their optimum dose, are given as examples in the following tables.
  • cyclophosphamide alkylating agent
  • 5-fluorouracil antimetabolite
  • etoposide semisynthetic podophyllotoxin agent
  • vincristine vinca alkaloid
  • the present invention also relates to pharmaceutical compositions containing the combinations according to the invention.
  • the products of which the combination are composed may be administered simultaneously, separately or spaced out over a period of time so as to obtain the maximum efficacy of the combination; it being possible for each administration to vary in its duration from a rapid administration to a continuous perfusion.
  • the combinations are not exclusively limited to those which are obtained by physical association of the constituents, but also to those which permit a separate administration, which can be simultaneous or spaced out over a period of time.
  • compositions according to the invention are preferably compositions which can be administered parentally. However, these compositions may be administered orally or intraperitoneally in the case of localized regional therapies.
  • compositions for parental administration are generally pharmaceutically acceptable, sterile solutions or suspensions which may optionally be prepared as required at the time of use.
  • natural vegetable oils such as olive oil, sesame oil or liquid petroleum or injectable organic esters such as ethyl oleate may be used.
  • the sterile aqueous solutions can consist of a solution of the product in water.
  • the aqueous solutions are suitable for intravenous administration provided the pH is appropriately adjusted and the solution is made isotonic, for example with a sufficient amount of sodium chloride or glucose.
  • the sterilization may be carried out by heating or by any other means which does not adversely affect the composition.
  • the combinations may also take the form of liposomes or the form of an association with carriers as cyclodextrins or polyethylene glycols.
  • compositions for oral or intraperitoneal administration are preferably aqueous suspensions or solutions.
  • the application of the constituents of which may be simultaneous, separate or spaced out over a period of time, it is especially advantageous for the amount of taxane derivative to represent from 10 to 90% by weight of the combination, it being possible for this content to vary in accordance with the nature of the associated substance, the efficacy sought and the nature of the cancer to be treated.
  • the combinations according to the invention are especially useful in the treatment of cancers of the breast, ovary or lung.
  • they can afford the advantage of being able to employ the constituents at considerably lower doses than those at which they are used alone.
  • 10-cm 3 ampoules containing 100 mg of Taxotere are prepared, for intravenous administration, according to the usual technique.
  • 5-cm 3 ampoules containing 100 mg of etoposide are prepared, for intravenous administration, according to the usual technique.
  • the treatment may be repeated several times daily or weakly until there is a partial or total remission or a cure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Antitumour combinations consisting of taxol or Taxotère or analogues thereof combined with at least one therapeutically useful substance for treating neoplastic diseases.

Description

  • The present invention relates to combinations of taxol, Taxotere and their analogues and substances which are therapeutically useful in the treatment of neoplastic diseases.
  • Taxol, Taxotere and their analogues, which possess noteworthy antitumour and antileukaemic properties, are especially useful in the treatment of cancers of the ovary, breast or lung.
  • The preparation of taxol, Taxotere and their derivatives form the subject, for example, of European Patents EP 0,253,738 and EP 0,253,739 and International Application PCT WO 92/09,589.
  • Generally, the doses used, which depend on factors distinctive to the subject to be treated, are between 1 and 10 mg/kg administered intraperitoneally or between 1 and 3 mg/kg administered intravenously.
  • It has now been found, and this forms the subject of the present invention, that the efficacy of taxol, Taxotere and their analogues may be considerably improved when they are administered in combination with at least one substance which is therapeutically useful in anticancer treatments and has a mechanism identical to or different from this of taxane derivatives.
  • Among substances which may be used in association or in combination with taxol, Taxotere or their analogues, there may be mentioned alkylating agents such as cyclophosphamide; isosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine, antimetabolites such as pyrimidine analogues, for instance 5-fluorouracil and cytarabine or its analogues such as 2-fluorodeoxycytidine, or folic acid analogues such as methotrexate, idatrexate or trimetrexate, spindle poisons including vinca alkaloids such as vinblastine or vincristine or their synthetic analogues such as navelbine, or estramustine or taxoids, epidophylloptoxins such as etoposide or teniposide, antibiotics such as daunorubicine, doxorubicin, bleomycin or mitomycin, enzymes such as L-asparaginase, topoisomerase inhibitors such as camptothecin derivatives chosen from CPT-11 and topotecan or pyridobenzoindole derivatives, and various agents such as procarbazine, mitoxantrone, platinum coordination complexes such as cisplatin or carboplatin, and biological response modifiers or growth factor inhibitors such as interferons or interleukins.
  • Moreover, since the activity of the products depends on the doses used, it is possible to use higher doses and to increase the activity while decreasing the toxicity phenomena or delaying their onset by combining growth factors of the haematopoietic type such as G-CSF or GM-CSF or certain interleukins with taxol, Taxotere, their analogues or their combinations with other therapeutically active substances.
  • The combinations or associations according to the invention enable the phenomenaa of pleiotropic resistance or “multi-drug resistance” to be avoided to delayed.
  • More especially, the invention relates to combinations of taxol, Taxotere and their analogues with vinca alkaloids, cyclophosphamide, 5-fluorouracil, doxorubicin, cisplatin and etoposide.
  • The improved efficacy of a combination according to the invention may be demonstrated by determination of the therapeutic synergy.
  • The efficacy of a combination according to the invention may also be characterized by adding the actions of each constituent.
  • A combination manifests therapeutic synergy if it is therapeutically superior to one or other of the constituents used at its optimum dose (T. H. CORBETT et al., Cancer Treatment Reports, 66, 1187 (1982))
  • To demonstrate the efficacy of a combination, it may be necessary to compare the maximum tolerated dose of the combination with the maximum tolerated dose of each of the separate constituents in the study in question. This efficacy may be quantified, for example by the log10 cells killed, which is determined according to the following formula:
    log10 cells killed=T−C(days)/3.32×T d
    in which T−C represents the time taken for the cells to grow, which is the mean time in days for the tumours of the treated group (T) and the tumours of the treated group (C) to have reached a predetermined value (1 g for example), and Td represents the time in days needed for the volume of the tumour to double in the control animals (T. H. CORBETT et al., Cancer, 40, 2660.2680 (1977); F. M. SCHABEL et al., Cancer Drug Development, Part B, Methods in Cancer Research, 17, 3-51, New York, Academic Press Inc. (1979)]. A product is considered to be active if log10 cells killed is greater than or equal to 0.7. A product is considered to be very active if log10 cells killed is greater than 2.8.
  • The combination, used at its own maximum tolerated dose, in which each of the constituents will be present at a dose generally not exceeding its maximum tolerated dose, will manifest therapeutic synergy when the log10 cells killed is greater than the value of the log10 cells killed of the best constituent when it is administered alone.
  • The efficacy of the combinations on solid tumours may be determined experimentally in the following manner:
  • The animals subjected to the experiment, generally mice, are subcutaneously grafted bilaterally with 30 to 60 mg of a tumour fragment on day 0. The animals bearing tumours are mixed before being subjected to the various treatments and controls. In the case of treatment of advanced tumours, tumours are allowed to develop to the desired size, animals having insufficiently developed tumours being eliminated. The selected animals are distributed at random to undergo the treatments and controls. Animals not bearing tumours may also be subjected to the same treatments as the tumour-bearing animals in order to be able to dissociate the toxic effect from the specific effect on the tumour. Chemotherapy generally begins from 3 to 22 days after grafting, depending on the type of tumour, and the animals are observed every day. The different animal groups are weighed 3 or 4 times a week until the maximum weight loss is attained, and the groups are then weighed at least once a week until the end of the trial.
  • The tumours are measured 2 or 3 times a week until the tumour reaches approximately 2 g, or until the animal dies if this occurs before the tumour reaches 2 g. The animals are autopsied when sacrificed.
  • The antitumour activity is determined in accordance with the different parameters recorded.
  • For a study of the combinations on leukaemias, the animals are grafted with a particular number of cells, and the antitumour activity is determined by the increase in the survival time of the treated mice relative to the controls. The product is considered to be active if the increase in survival time is greater than 27%, and is considered to be very active if it is greater than 75% in the case of P388 leukaemia.
  • The results obtained with combinations of Taxotere and various chemotherapeutic agents, such as cyclophosphamide (alkylating agent), 5-fluorouracil (antimetabolite), etoposide (semisynthetic podophyllotoxin agent) and vincristine (vinca alkaloid), the combinations being used at their optimum dose, are given as examples in the following tables.
    TABLE 1
    Activity of the combination Taxotere + cyclophosphamide at the
    optimium dose against advanced MA13/c mammary adenocarcinoma
    grafted subcutaneously
    Dose Total log10
    mg/kg/injection Administration dose cells
    Product i.v. on days: mg/kg killed
    Taxotere 15 14, 17, 20 45 2.8
    Cylcophos- 118 14 118 1.3
    phamide
    Taxotere + 7.5 14, 17, 20, 14 22.5 3.4
    cyclophos- 90.0 90
    phamide
  • TABLE 2
    Activity of the combination Taxotere + etoposide at the optimum
    dose against early B16 melanoma grafted subcutaneously
    Dose Total log10
    mg/kg/injection Administration dose cells
    Product i.v. on days: mg/kg killed
    Taxotere 17.5 4, 7, 10, 13 70 2.8
    Etoposide 46.2 4, 7, 10, 13 184.8 2.8
    Taxotere + 15.7 4, 7, 10, 13 62.8 4.1
    etoposide 13.8 (simultaneous) 55.2
  • TABLE 3
    Activity of the combination Taxotere + 5-fluorouracil at the
    optimum dose against advanced C38 colon adenocarcinoma grafted
    subcutaneously
    Dose Total log10
    mg/kg/injection Administration dose cells
    Product i.v. on days: mg/kg killed
    Taxotere 22 21, 25, 29, 33 88.0 1.4
    5-fluorouracil 43.4 21, 25, 29, 33 173.6 1.1
    Taxotere + 17.6 21, 25, 29, 33 70.4 4.8.
    5-fluorouracil 27.0 (simultaneous) 108.0
  • TABLE 4
    Activity of the combination Taxotere + vincristine at the
    optimum dose against P388 leukaemia (106 cells i.p.)
    Dose Total log10
    mg/kg/injection Administration dose cells
    Product i.v. on days: mg/kg killed
    Taxotere 17.5 4, 7, 10, 13 70 2.8
    vincristine 46.2 4, 7, 10, 13 184.8 2.8
    Taxotere + 21.75 1, 4, 7 65.25 62
    vincristine 1.2 (simultaneous) 3.6
    Taxotere + 21.75 1, 4, 7 65.25 77
    vincristine 1.2 (4 hours 3.6
    apart)
  • The present invention also relates to pharmaceutical compositions containing the combinations according to the invention.
  • The products of which the combination are composed may be administered simultaneously, separately or spaced out over a period of time so as to obtain the maximum efficacy of the combination; it being possible for each administration to vary in its duration from a rapid administration to a continuous perfusion.
  • As a result, for the purposes of the present invention, the combinations are not exclusively limited to those which are obtained by physical association of the constituents, but also to those which permit a separate administration, which can be simultaneous or spaced out over a period of time.
  • The compositions according to the invention are preferably compositions which can be administered parentally. However, these compositions may be administered orally or intraperitoneally in the case of localized regional therapies.
  • The compositions for parental administration are generally pharmaceutically acceptable, sterile solutions or suspensions which may optionally be prepared as required at the time of use. For the preparation of non-aqueous solutions or suspensions, natural vegetable oils such as olive oil, sesame oil or liquid petroleum or injectable organic esters such as ethyl oleate may be used. The sterile aqueous solutions can consist of a solution of the product in water. The aqueous solutions are suitable for intravenous administration provided the pH is appropriately adjusted and the solution is made isotonic, for example with a sufficient amount of sodium chloride or glucose. The sterilization may be carried out by heating or by any other means which does not adversely affect the composition. The combinations may also take the form of liposomes or the form of an association with carriers as cyclodextrins or polyethylene glycols.
  • The compositions for oral or intraperitoneal administration are preferably aqueous suspensions or solutions.
  • In the combinations according to the invention, the application of the constituents of which may be simultaneous, separate or spaced out over a period of time, it is especially advantageous for the amount of taxane derivative to represent from 10 to 90% by weight of the combination, it being possible for this content to vary in accordance with the nature of the associated substance, the efficacy sought and the nature of the cancer to be treated.
  • The combinations according to the invention are especially useful in the treatment of cancers of the breast, ovary or lung. In particular, they can afford the advantage of being able to employ the constituents at considerably lower doses than those at which they are used alone.
  • The example which follows illustrates a combination according to the invention.
    • EXAMPLE
  • 10-cm3 ampoules containing 100 mg of Taxotere are prepared, for intravenous administration, according to the usual technique.
  • 5-cm3 ampoules containing 100 mg of etoposide are prepared, for intravenous administration, according to the usual technique.
  • These solutions are administered simultaneously, after appropriate dilution, by perfusion.
  • The treatment may be repeated several times daily or weakly until there is a partial or total remission or a cure.

Claims (12)

1-14. (canceled)
15. A method of treating a neoplastic disease in a patient in need thereof, comprising administering to the patient
an effective amount of at least one taxane chosen from taxol, docetaxel, and derivatives thereof, and
an effective amount of at least one topoisomerase inhibitor chosen from camptothecin, CPT-11, topotecan, and pyridobenzoindole,
wherein the at least one taxane and at least one topoisomerase inhibitor exhibit therapeutic synergy.
16. The method of claim 15, wherein the effective amount of the at least one taxane is not greater than the maximum tolerated dose of the at least one taxane.
17. The method of claim 15, wherein the effective amount of the at least one topoisomerase inhibitor is not greater than the maximum tolerated dose of the at least one topoisomerase inhibitor.
18. The method of claim 15, wherein the at least one topoisomerase inhibitor comprises camptothecin.
19. The method of claim 15, wherein the at least one topoisomerase inhibitor comprises CPT-11.
20. The method of claim 15, wherein the at least one taxane and the at least one topoisomerase inhibitor are administered simultaneously.
21. The method of claim 15, wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and simultaneously.
22. The method of claim 15, wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and sequentially.
23. The method of claim 19, wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and sequentially.
24. The method of claim 19, wherein the at least one taxane and the at least one topoisomerase inhibitor are administered simultaneously.
25. The method of claim 19, wherein the at least one taxane and the at least one topoisomerase inhibitor are administered separately and simultaneously.
US11/149,178 1992-11-10 2005-06-10 Antitumour compositions containing taxane derivatives Abandoned US20050226940A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/149,178 US20050226940A1 (en) 1992-11-10 2005-06-10 Antitumour compositions containing taxane derivatives

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
FR9213525 1992-11-10
FR9213525A FR2697752B1 (en) 1992-11-10 1992-11-10 Antitumor compositions containing taxane derivatives.
US08/424,470 US5728687A (en) 1992-11-10 1993-11-08 Antitumour compositions containing taxane derivatives
PCT/FR1993/001096 WO1994010995A1 (en) 1992-11-10 1993-11-08 Antitumour compositions containing taxane derivatives
US08/967,036 US5908835A (en) 1992-11-10 1997-11-10 Anti-tumor compositions containing taxane derivatives
US18290098A 1998-10-30 1998-10-30
US09/371,520 US6214863B1 (en) 1992-11-10 1999-08-10 Antitumor compositions containing taxane derivatives
US09/506,902 US6239167B1 (en) 1992-11-10 2000-02-18 Antitumor compositions containing taxane derivatives
US70573900A 2000-11-06 2000-11-06
US10/134,391 US20020197245A1 (en) 1992-11-10 2002-04-30 Antitumour compositions containing taxane derivatives
US11/149,178 US20050226940A1 (en) 1992-11-10 2005-06-10 Antitumour compositions containing taxane derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/134,391 Division US20020197245A1 (en) 1992-11-10 2002-04-30 Antitumour compositions containing taxane derivatives

Publications (1)

Publication Number Publication Date
US20050226940A1 true US20050226940A1 (en) 2005-10-13

Family

ID=9435406

Family Applications (13)

Application Number Title Priority Date Filing Date
US08/424,470 Expired - Lifetime US5728687A (en) 1992-11-10 1993-11-08 Antitumour compositions containing taxane derivatives
US08/967,036 Expired - Lifetime US5908835A (en) 1992-11-10 1997-11-10 Anti-tumor compositions containing taxane derivatives
US09/371,520 Expired - Lifetime US6214863B1 (en) 1992-11-10 1999-08-10 Antitumor compositions containing taxane derivatives
US09/506,902 Expired - Lifetime US6239167B1 (en) 1992-11-10 2000-02-18 Antitumor compositions containing taxane derivatives
US10/134,391 Abandoned US20020197245A1 (en) 1992-11-10 2002-04-30 Antitumour compositions containing taxane derivatives
US10/422,823 Expired - Fee Related US7989489B2 (en) 1992-11-10 2003-04-25 Method of treating leukemia with docetaxel and vinca alkaloids
US10/747,207 Abandoned US20040157786A1 (en) 1992-11-10 2003-12-30 Antitumor combinations containing taxane derivatives and platinum coordination complexes
US10/747,372 Expired - Fee Related US8124650B2 (en) 1992-11-10 2003-12-30 Antitumor combinations containing taxane derivatives and epidophyllotoxins
US10/747,279 Expired - Fee Related US8101652B2 (en) 1992-11-10 2003-12-30 Antitumour combinations containing taxotere and 5-fluorouracil
US10/747,206 Expired - Fee Related US7994212B2 (en) 1992-11-10 2003-12-30 Method of treating cancer with docetaxel and doxorubicin
US10/747,410 Abandoned US20040152673A1 (en) 1992-11-10 2003-12-30 Antitumor combinations containing taxane derivatives and alkylating agents
US11/149,178 Abandoned US20050226940A1 (en) 1992-11-10 2005-06-10 Antitumour compositions containing taxane derivatives
US13/173,268 Abandoned US20110263522A1 (en) 1992-11-10 2011-06-30 Antitumour compositions containing taxane derivatives

Family Applications Before (11)

Application Number Title Priority Date Filing Date
US08/424,470 Expired - Lifetime US5728687A (en) 1992-11-10 1993-11-08 Antitumour compositions containing taxane derivatives
US08/967,036 Expired - Lifetime US5908835A (en) 1992-11-10 1997-11-10 Anti-tumor compositions containing taxane derivatives
US09/371,520 Expired - Lifetime US6214863B1 (en) 1992-11-10 1999-08-10 Antitumor compositions containing taxane derivatives
US09/506,902 Expired - Lifetime US6239167B1 (en) 1992-11-10 2000-02-18 Antitumor compositions containing taxane derivatives
US10/134,391 Abandoned US20020197245A1 (en) 1992-11-10 2002-04-30 Antitumour compositions containing taxane derivatives
US10/422,823 Expired - Fee Related US7989489B2 (en) 1992-11-10 2003-04-25 Method of treating leukemia with docetaxel and vinca alkaloids
US10/747,207 Abandoned US20040157786A1 (en) 1992-11-10 2003-12-30 Antitumor combinations containing taxane derivatives and platinum coordination complexes
US10/747,372 Expired - Fee Related US8124650B2 (en) 1992-11-10 2003-12-30 Antitumor combinations containing taxane derivatives and epidophyllotoxins
US10/747,279 Expired - Fee Related US8101652B2 (en) 1992-11-10 2003-12-30 Antitumour combinations containing taxotere and 5-fluorouracil
US10/747,206 Expired - Fee Related US7994212B2 (en) 1992-11-10 2003-12-30 Method of treating cancer with docetaxel and doxorubicin
US10/747,410 Abandoned US20040152673A1 (en) 1992-11-10 2003-12-30 Antitumor combinations containing taxane derivatives and alkylating agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/173,268 Abandoned US20110263522A1 (en) 1992-11-10 2011-06-30 Antitumour compositions containing taxane derivatives

Country Status (25)

Country Link
US (13) US5728687A (en)
EP (4) EP1093811A1 (en)
JP (1) JP3974938B2 (en)
KR (2) KR100334051B1 (en)
AT (2) ATE165002T1 (en)
AU (1) AU680845B2 (en)
CA (1) CA2149055C (en)
CZ (2) CZ288033B6 (en)
DE (2) DE69330724T2 (en)
DK (2) DK0667771T3 (en)
ES (2) ES2163076T3 (en)
FI (1) FI952248A (en)
FR (1) FR2697752B1 (en)
GR (2) GR3026666T3 (en)
HU (1) HU223773B1 (en)
MX (1) MX9306924A (en)
NO (1) NO315027B1 (en)
NZ (1) NZ257585A (en)
PL (1) PL173951B1 (en)
PT (1) PT827745E (en)
RU (1) RU2131250C1 (en)
SK (1) SK282867B6 (en)
TW (1) TW386877B (en)
WO (1) WO1994010995A1 (en)
ZA (1) ZA938182B (en)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2697752B1 (en) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
FR2698871B1 (en) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
FR2729295A1 (en) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa COMBINED THERAPEUTIC TREATMENT OF HYPERPROLIFERATIVE CONDITIONS
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6011069A (en) * 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
CA2246734A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6740497B2 (en) * 1998-03-06 2004-05-25 The Regents Of The University Of California Method and apparatus for detecting cancerous cells using molecules that change electrophoretic mobility
US6335201B1 (en) * 1998-03-06 2002-01-01 The Regents Of The University Of California Method and apparatus for detecting enzymatic activity using molecules that change electrophoretic mobility
EA004647B1 (en) * 1998-03-27 2004-06-24 Фармация Энд Апджон Компани Methods of potentiating of intravenous phosphate
US6849616B1 (en) 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
BR9909393A (en) * 1998-04-03 2000-12-26 Ajinomoto Kk Antitumor agent, use of a stilbene derivative and a platinum coordination compound, and, process for the treatment or improvement of a tumor
WO1999056742A1 (en) * 1998-05-04 1999-11-11 Auckland Uniservices Limited Chemotherapeutic treatment
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
WO2000006134A2 (en) * 1998-07-30 2000-02-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
DE60031268T2 (en) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston METHOD AND COMPOSITION FOR THE TREATMENT OF CANCER
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6737240B1 (en) * 1999-05-25 2004-05-18 Rigel Pharmaceuticals, Inc. Methods of screening for a multi-drug resistance conferring peptide
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
CH694589A5 (en) * 1999-06-25 2005-04-15 Genentech Inc Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies.
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
PT1189634E (en) * 1999-06-25 2007-06-06 Genentech Inc Treating prostate cancer with anti-erbb2 antibodies
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
IL148114A0 (en) 1999-08-27 2002-09-12 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
IL145636A0 (en) 2000-02-02 2002-06-30 Univ Florida State Res Found C10 carbonate substituted taxanes as antitumor agents
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
EP2295456A1 (en) * 2000-04-12 2011-03-16 Human Genome Sciences, Inc. Albumin fusion proteins
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
MXPA02011319A (en) * 2000-05-15 2003-06-06 Pharma Mar Sa Antitumoral analogs of et 743.
PL217410B1 (en) * 2000-05-19 2014-07-31 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
PL366100A1 (en) * 2000-09-22 2005-01-24 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
RU2178702C1 (en) * 2001-02-21 2002-01-27 Общество с ограниченной ответственностью "Нобель" Anticancer agent
US6703400B2 (en) * 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
RU2284184C2 (en) * 2001-03-06 2006-09-27 Бристол-Маерс Сквибб Компани Method for treating cancer
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7691872B2 (en) * 2001-03-20 2010-04-06 University Of Kentucky Research Foundation Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
UY27220A1 (en) * 2001-03-23 2002-09-30 Aventis Pharma Sa COMBINATION OF A TAXAN WITH A CYCLINE-DEPENDENT KINASE
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
JP2005508323A (en) * 2001-09-26 2005-03-31 インターミューン インコーポレイテッド Pharmaceutical compositions and methods for cancer treatment
AU2002343548B2 (en) * 2001-10-19 2007-11-08 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc Albumin fusion proteins
EP1463751B1 (en) * 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
US7426479B2 (en) * 2002-03-12 2008-09-16 Ncr Corporation Customer activity data system and method
US6593334B1 (en) * 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
JP4773719B2 (en) * 2002-05-17 2011-09-14 アベンティス・ファーマ・ソシエテ・アノニム Use of docetaxel / doxorubicin / cyclophosphamide in adjuvant therapy of breast and ovarian cancer
NZ538498A (en) * 2002-07-30 2009-02-28 Childrens Medical Center Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
JP2006516117A (en) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド Treatment of non-malignant diseases or disorders using anti-ErbB2 antibodies
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US20040229931A1 (en) * 2003-04-30 2004-11-18 Aventis Pharma S. A. 1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use
EP1663153A4 (en) * 2003-05-20 2011-01-05 Aronex Pharmaceuticals Inc Combination chemotherapy comprising a liposomal platinum complex
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
ATE406897T1 (en) * 2003-11-13 2008-09-15 Pharma Mar Sau COMBINATION OF ET-743 WITH 5-FLUOROURACIL PRO-DRUGS FOR THE TREATMENT OF CANCER
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
MXPA06009547A (en) * 2004-02-23 2007-01-26 Dana Farber Cancer Inst Inc Method of treating abnormal cell growth using c-met and-tor inhibitors.
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
EP2305642A3 (en) 2004-06-23 2011-12-14 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
JP2008514688A (en) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル Etainacidin compounds as anti-inflammatory agents
PT1827500E (en) * 2004-10-26 2009-08-05 Pharma Mar Sa Pegylated liposomal doxorubicin in combination with ecteinescidin 743
PT1658848E (en) * 2004-10-29 2007-11-05 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
US20060194756A1 (en) * 2004-11-22 2006-08-31 Borea Pier A Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
HUE038768T2 (en) * 2005-02-18 2018-11-28 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
DK2343320T3 (en) * 2005-03-25 2018-01-29 Gitr Inc ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
JP2008536875A (en) 2005-04-15 2008-09-11 シンタ ファーマシューティカルズ コーポレーション Combined cancer therapy with bis (thiohydrazide) amide compounds
JP2008540658A (en) 2005-05-16 2008-11-20 シンタ ファーマシューティカルズ コーポレーション Synthesis of bis (thio-hydrazide amide) salts
MX2007015534A (en) * 2005-06-07 2008-02-25 Univ Yale Methods of treating cancer and other conditions or disease states using lfmau and ldt.
US7678832B2 (en) 2005-08-16 2010-03-16 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
CA2624086A1 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
JP5688877B2 (en) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Quinazoline derivatives for the treatment of cancer diseases
WO2007104011A2 (en) * 2006-03-08 2007-09-13 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
JP2010501562A (en) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション Compounds for treating proliferative disorders
US7939564B2 (en) 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
WO2008033494A2 (en) 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
ATE552835T1 (en) 2006-09-18 2012-04-15 Boehringer Ingelheim Int METHOD FOR TREATING TUMORS WITH EGFR MUTATIONS
FR2907341B1 (en) * 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
WO2008082579A1 (en) * 2007-01-03 2008-07-10 Synta Pharmaceuticals Corp. Method for treating cancer
ES2591281T3 (en) * 2007-07-12 2016-11-25 Gitr, Inc. Combination therapies that employ GITR binding molecules
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
DK2451445T3 (en) 2009-07-06 2019-06-24 Boehringer Ingelheim Int PROCEDURE FOR DRYING BIBW2992, IT'S SALTS AND SOLID PHARMACEUTICAL FORMULATIONS INCLUDING THIS ACTIVE INGREDIENT
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201503593UA (en) 2012-11-13 2015-06-29 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CR20210097A (en) 2014-03-21 2022-04-27 Abbvie Inc Anti-egfr antibodies and antibody drug conjugates
US10080807B2 (en) 2014-06-09 2018-09-25 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin C
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
TW202304996A (en) 2016-06-08 2023-02-01 美商艾伯維有限公司 Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075630A2 (en) 2016-06-08 2019-03-19 Abbvie Inc. anti-cd98 antibodies and antibody drug conjugates
CN109641962A (en) 2016-06-08 2019-04-16 艾伯维公司 Anti- B7-H3 antibody and antibody drug conjugates
RU2680834C1 (en) * 2018-05-23 2019-02-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Antitumor composition of doxorubicin with atp inhibitor-dependent reverse cell transporter
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4857653A (en) * 1986-07-17 1989-08-15 Rhone-Poulenc Sante Process for the preparation of taxol and 10-deacetyltaxol
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4892735A (en) * 1988-03-16 1990-01-09 Johnson Matthey Public Limited Company Platinum chemotherapeutic product
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5262409A (en) * 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5294737A (en) * 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
US5466834A (en) * 1991-09-23 1995-11-14 Florida State University Preparation of substituted isoserine esters using metal alkoxides and .beta.
US5476954A (en) * 1990-11-23 1995-12-19 Rhone-Poulenc Rorer S.A. Process for preparing taxane derivatives, new derivatives obtained and pharmaceutical compositions containing them
US5494683A (en) * 1991-01-25 1996-02-27 Eastman Kodak Company Surface modified anticancer nanoparticles
US5532388A (en) * 1992-12-09 1996-07-02 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US5645988A (en) * 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5728687A (en) * 1992-11-10 1998-03-17 Rhone-Poulenc Rorer, S.A. Antitumour compositions containing taxane derivatives
US5814658A (en) * 1992-12-09 1998-09-29 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623089B1 (en) * 1987-11-13 1990-04-27 Pf Medicament PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION OF NAVELBINE
AU2005692A (en) * 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5495501A (en) * 1992-09-02 1996-02-27 Fujitsu Limited Communication system including a digital roll-off filter
MX9307777A (en) 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METHANE-TAXOLES, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
CA2176706C (en) 1993-12-03 2006-01-24 Stanley J. Brois Carbonyl containing compounds
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP0982028A1 (en) 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives
US7696923B2 (en) * 2005-02-03 2010-04-13 Mexens Intellectual Property Holding Llc System and method for determining geographic location of wireless computing devices

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4857653A (en) * 1986-07-17 1989-08-15 Rhone-Poulenc Sante Process for the preparation of taxol and 10-deacetyltaxol
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4892735A (en) * 1988-03-16 1990-01-09 Johnson Matthey Public Limited Company Platinum chemotherapeutic product
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5476954A (en) * 1990-11-23 1995-12-19 Rhone-Poulenc Rorer S.A. Process for preparing taxane derivatives, new derivatives obtained and pharmaceutical compositions containing them
US5494683A (en) * 1991-01-25 1996-02-27 Eastman Kodak Company Surface modified anticancer nanoparticles
US5645988A (en) * 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5466834A (en) * 1991-09-23 1995-11-14 Florida State University Preparation of substituted isoserine esters using metal alkoxides and .beta.
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) * 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) * 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US6214863B1 (en) * 1992-11-10 2001-04-10 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5728687A (en) * 1992-11-10 1998-03-17 Rhone-Poulenc Rorer, S.A. Antitumour compositions containing taxane derivatives
US5908835A (en) * 1992-11-10 1999-06-01 Rhone-Poulenc Rorer, S.A. Anti-tumor compositions containing taxane derivatives
US6239167B1 (en) * 1992-11-10 2001-05-29 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5532388A (en) * 1992-12-09 1996-07-02 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US5814658A (en) * 1992-12-09 1998-09-29 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs

Also Published As

Publication number Publication date
TW386877B (en) 2000-04-11
ZA938182B (en) 1994-06-09
CZ290120B6 (en) 2002-06-12
WO1994010995A1 (en) 1994-05-26
HU9501372D0 (en) 1995-06-28
EP0667771B1 (en) 1998-04-15
US8101652B2 (en) 2012-01-24
EP0667771A1 (en) 1995-08-23
US20040157786A1 (en) 2004-08-12
JPH08503205A (en) 1996-04-09
US20040152644A1 (en) 2004-08-05
NO315027B1 (en) 2003-06-30
FI952248A0 (en) 1995-05-09
US20040152642A1 (en) 2004-08-05
US8124650B2 (en) 2012-02-28
HU223773B1 (en) 2005-01-28
US6239167B1 (en) 2001-05-29
CA2149055A1 (en) 1994-05-26
EP1093811A1 (en) 2001-04-25
EP0827745A1 (en) 1998-03-11
US20020197245A1 (en) 2002-12-26
US7994212B2 (en) 2011-08-09
ES2163076T3 (en) 2002-01-16
KR950703945A (en) 1995-11-17
RU2131250C1 (en) 1999-06-10
NO951327D0 (en) 1995-04-05
DE69330724T2 (en) 2002-07-11
DE69318033T2 (en) 1998-10-22
DK0827745T3 (en) 2001-11-19
FR2697752B1 (en) 1995-04-14
JP3974938B2 (en) 2007-09-12
US7989489B2 (en) 2011-08-02
CZ288033B6 (en) 2001-04-11
PT827745E (en) 2002-02-28
PL308902A1 (en) 1995-09-04
US20110263522A1 (en) 2011-10-27
US20040152673A1 (en) 2004-08-05
ATE205083T1 (en) 2001-09-15
DE69330724D1 (en) 2001-10-11
US6214863B1 (en) 2001-04-10
GR3026666T3 (en) 1998-07-31
NO951327L (en) 1995-04-05
MX9306924A (en) 1994-05-31
PL173951B1 (en) 1998-05-29
GR3036537T3 (en) 2001-12-31
EP1295597A1 (en) 2003-03-26
AU5425394A (en) 1994-06-08
FR2697752A1 (en) 1994-05-13
KR100334051B1 (en) 2002-09-04
ES2114620T3 (en) 1998-06-01
SK59595A3 (en) 1996-05-08
NZ257585A (en) 1996-06-25
US5908835A (en) 1999-06-01
CA2149055C (en) 2003-01-07
AU680845B2 (en) 1997-08-14
HUT72499A (en) 1996-05-28
ATE165002T1 (en) 1998-05-15
KR20030096445A (en) 2003-12-31
US20040013660A1 (en) 2004-01-22
DK0667771T3 (en) 1998-10-07
SK282867B6 (en) 2003-01-09
US20040152643A1 (en) 2004-08-05
FI952248A (en) 1995-05-09
CZ119395A3 (en) 1995-10-18
DE69318033D1 (en) 1998-05-20
EP0827745B1 (en) 2001-09-05
US5728687A (en) 1998-03-17

Similar Documents

Publication Publication Date Title
US7989489B2 (en) Method of treating leukemia with docetaxel and vinca alkaloids
US6441026B1 (en) Antitumor compositions containing taxane derivatives
AU2002244877A1 (en) Antitumor compositions containing taxane derivatives
AU2002221622B2 (en) Antitumor therapy comprising distamycin derivatives
Ghaemmaghami et al. New agents in the treatment of small cell lung cancer

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION